T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1879-1886

  Schure, Rose Minke ^a,b   Hendrikx, Lotte H ^c   De Rond, Lia G H ^a   Öztürk, Kemal ^a   Sanders, Elisabeth A M ^b   Berbers, Guy A M ^a   Buisman, Anne Marie ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INFANRIX IPV HIB; INTERLEUKIN 10; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFANT; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; NETHERLANDS; OBSERVATIONAL STUDY; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HUMANS; IMMUNOGLOBULIN E; INFANT; INTERFERON-GAMMA; INTERLEUKIN-10; NETHERLANDS; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; TH2 CELLS; VACCINATION; VACCINES, ACELLULAR;

EID: 84868245290     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00277-12     Document Type: Article

References (39)

1. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. 1997. Vaccineand antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:2168-2174. (Pubitemid 27237293)
2. Berbers GA, de Greeff SC, Mooi FR. 2009. Improving pertussis vaccination. Hum. Vaccin. 5:497-503.
3. Buisman AM, de Rond CG, Ozturk K, Ten Hulscher HI, van Binnendijk RS. 2009. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 28:179-186.
4. California Department of Public Health. 6 January 2012. Pertussis report. California Department of Public Health, Sacramento, CA. http://www.cdph.ca.gov/ programs/immunize/Documents/PertussisReport1-6-2012.pdf.
5. Cassone A, et al. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch. Pediatr. Adolesc. Med. 151:283-289.
6. Constant SL, Bottomly K. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297-322. (Pubitemid 27169283)
7. de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR. 2011. Pertussis: a matter of immune modulation. FEMS Microbiol. Rev. 35:441-474.
8. de Greeff SC, et al. 2010. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 5:e14183. doi:10.1371/journal.pone.0014183.
9. de Melker HE, et al. 2000. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J. Clin. Microbiol. 38:800-806. (Pubitemid 30082684)
10. Dubin PJ, Kolls JK. 2008. Th17 cytokines and mucosal immunity. Immunol. Rev. 226:160-171.
11. Edelman K, et al. 1999. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur. J. Pediatr. 158:989-994.
12. Guiso N, et al. 2007. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25:1390-1397. (Pubitemid 46091822)
13. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM. 2009. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27:6530-6536.
14. Hendrikx LH, et al. 2011. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Vaccine 29:5725-5730.
15. Hendrikx LH, et al. 2011. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine 29:6874-6880.
16. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177:7980-7989. (Pubitemid 44846315)
17. Keller GN, et al. 1999. The determination of endotoxin in the finished cellular product. Cytotherapy 1:423-428.
18. Kemmeren JM, Timmer SS, van der Maas NA, de Melker HE. 2011. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children. Vaccine 29:4373-4377.
19. Kuehn BM. 2010. Panel backs wider pertussis vaccination to curb outbreaks, prevent deaths. JAMA 304:2684-2686.
20. Lalor MK, et al. 2011. BCG vaccination induces different cytokine profiles following infantBCGvaccination in theUKand Malawi. J. Infect. Dis. 204:1075-1085.
21. Le T, et al. 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J. Infect. Dis. 190:535-544. (Pubitemid 38982093)
22. Loosmore SM, et al. 1995. Hybrid genes over-express pertactin from Bordetella pertussis. Vaccine 13:571-580.
23. Mascart F, et al. 2007. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25:391-398. (Pubitemid 44873143)
24. Mertsola J, et al. 2010. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin. Infect. Dis. 51:656-662.
25. Miller E, et al. 1997. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15:51-60. (Pubitemid 27060001)
26. Mills KH. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655-677. (Pubitemid 32607761)
27. Mooi FR, et al. 1998. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66:670-675. (Pubitemid 28074211)
28. Nilsson L, Gruber C, Granstrom M, Bjorksten B, Kjellman NI. 1998. Pertussis IgE and atopic disease. Allergy 53:1195-1201. (Pubitemid 29037993)
29. Poulter LW, Seymour GJ, Duke O, Janossy G, Panayi G. 1982. Immunohistological analysis of delayed-type hypersensitivity in man. Cell. Immunol. 74:358-369. (Pubitemid 13147284)
30. Quinn P, et al. 2011. Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old. Vaccine 29: 4230-4237.
31. Renz H, et al. 2002. T(H)1/T(H)2 immune response profiles differ between atopic children in eastern and western Germany. J. Allergy Clin. Immunol. 109:338-342. (Pubitemid 34158303)
32. Rieber N, et al. 2008. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Vaccine 26:6929-6935.
33. Rowe J, et al. 2005. Th2-associated local reactions to the acellular diphtheria- tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun. 73:8130-8135. (Pubitemid 41740300)
34. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH. 2000. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin. Exp. Immunol. 121:193-200. (Pubitemid 30659755)
35. Scheifele DW, Ochnio JJ, Halperin SA. 2009. Cellular Immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr. Infect. Dis. J. 28:985-989.
36. Schure RM, et al. 2012. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One 7:e41928. doi:10.1371/ journal.pone.0041928.
37. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. 2008. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J. Immunol. Methods 335:79-89.
38. Ward JI, et al. 2005. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 353:1555-1563. (Pubitemid 41434634)
39. Zepp F, et al. 2011. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11:557-570.